Polsart Plus

Quick links to important sections

Polsart Plus

Method of action: Antihypertensive, Diuretic

Treatment option: Hypertension

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Polsart Plus

Quick Facts

Property Description
Active Ingredients Telmisartan and Hydrochlorothiazide (HCTZ)
Form Oral tablet
Pharmacological Class Antihypertensive agent (ARB + Thiazide Diuretic)
Common Use Management of high blood pressure (Hypertension)
Origin Synthetic

What Type of Medicine is Polsart Plus? (Identity and Class)

Polsart Plus is a prescription-only medicine classified as an antihypertensive agent used for the management of high blood pressure, or essential hypertension. It is explicitly defined as a fixed-dose combination (FDC) product, meaning it contains two chemically distinct synthetic active pharmaceutical ingredients in a single oral tablet. This specific formulation, combining an Angiotensin II Receptor Blocker (ARB) with a Thiazide Diuretic, is clinically recognized for providing additive blood pressure reduction compared to either agent used alone.


What is Polsart Plus Made Of? (Composition and Active Agents)

The composition of Polsart Plus includes the active ingredients Telmisartan and Hydrochlorothiazide (HCTZ). Telmisartan acts to block a receptor that causes blood vessel tightening, while HCTZ acts on the kidneys to increase the excretion of water and sodium. This formulation represents a bi-component therapy, distinguished from other Telmisartan combinations by its inclusion of a diuretic component. The underlying generic combination, Telmisartan/Hydrochlorothiazide, is widely available under various brand names, confirming its established role in treating hypertension.


What is the General Purpose of This Combination Therapy?

The general purpose of the Polsart Plus combination is to achieve substantial, sustained systemic blood pressure reduction. The fixed pairing is typically used when essential hypertension is not adequately controlled by a single antihypertensive agent taken individually. Clinical evidence confirms that combining an ARB and a diuretic provides an effective method for achieving target blood pressure goals. The intended result is a reduced mechanical workload on the cardiovascular system, which is critical for mitigating the long-term risks associated with chronic high blood pressure.

Regulatory References

  1. European Medicines Agency (EMA)
  2. U.S. National Library of Medicine

What side effects are possible with Polsart Plus?

Possible Side Effects and Safety Information

The safety profile of Polsart Plus (Telmisartan/Hydrochlorothiazide) is organized according to official regulatory classifications that detail documented adverse reactions and safety restrictions. These classifications establish the expected range of effects, from frequently reported symptoms to critical safety limitations.


Frequency-Classified Adverse Reactions

The official labeling organizes side effects by their frequency in clinical study populations:

  • Common (affecting 1 to 10 users in 100) effects include dizziness, hypotension (low blood pressure, particularly orthostatic), and fatigue.
  • Uncommon effects include syncope, vertigo, headache, tachycardia, and various gastrointestinal disturbances.
  • Rare reactions documented include angioedema, a serious hypersensitivity reaction, and cases of impaired hepatic function.

System-Organ Class (SOC) Grouping and Serious Reactions

Adverse reactions are formally grouped by the affected body system, including Vascular disorders (hypotension), Nervous system disorders (dizziness), and Metabolism and nutrition disorders (electrolyte imbalances like hypokalemia).

The most serious safety concerns explicitly documented include fetal toxicity when used during the second and third trimesters of pregnancy, which can result in injury or death to the fetus, and the rare but severe risk of acute angle-closure glaucoma and angioedema.


Population-Specific Safety Considerations

The medicine is subject to strict regulatory limitations for certain patient groups:

  • Pregnancy: It is contraindicated in the second and third trimesters.
  • Impairment: It is contraindicated in patients with severe renal impairment (Creatinine Clearance < 30 ml/min) and severe hepatic impairment.

Safety documents note that Hypotension and Dizziness are most likely to occur at the beginning of treatment or during dose escalation, while electrolyte monitoring may be necessary during long-term exposure.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents define the overdose profile for Polsart Plus (olmesartan medoxomil and hydrochlorothiazide) based on the combined effects of its components. Immediate medical assistance must be sought for any suspected overdose.

Overdosage with the olmesartan component primarily results in effects on the cardiovascular system. The most likely manifestations are severe low blood pressure (hypotension) and a rapid heart rate (tachycardia). A slow heart rate (bradycardia) may also occur. These symptoms require prompt supportive treatment to stabilize circulation.

Overdosage with the hydrochlorothiazide component is characterized by signs and symptoms resulting from excessive loss of fluid and electrolytes due to increased urination. This can lead to dehydration and a serious depletion of essential electrolytes, including low potassium (hypokalemia), low sodium (hyponatremia), and low chloride (hypochloremia).

Primary Overdose Risks Associated Manifestations
Cardiovascular Instability Severe Hypotension, Tachycardia, Bradycardia
Electrolyte & Fluid Imbalance Dehydration, Hypokalemia, Hyponatremia

In cases where the patient is also taking digitalis, the hypokalemia resulting from a hydrochlorothiazide overdose may dangerously accentuate the risk of cardiac arrhythmias. Due to the severity of these potential outcomes, contact with a regional poison control centre is required for guidance in managing a suspected overdose.

Therapeutic Uses of Polsart Plus

What Polsart Plus Treats: Main Uses and Benefits

Polsart Plus is a combination medication generally applied in the management of high blood pressure, known as hypertension. It may be used to support patient health in situations linked to cardiovascular risk, especially when applied in scenarios where additional management of discomfort is needed.

It is relevant in clinical settings involving heightened systemic burden, providing supportive relief for symptoms related to systemic imbalance and increased physiological activity. It is commonly used across conditions presenting with acute episodes and fluctuating manifestations.

“This symptomatic relief may help patients cope more steadily with symptom fluctuations.”

Quick Fact: Support for Symptoms of Increased Physiological Activity The medicine assists with maintaining functional stability and supports the patient during difficult episodes by easing distress in contexts marked by increased discomfort or tension.

Eligibility and Restrictions for Use

Who Can and Cannot Use Polsart Plus? (Official Regulatory Information)

Category Official Regulatory Statement
Populations for whom use is allowed Adults whose high blood pressure is not adequately controlled by Telmisartan monotherapy alone.
Populations for whom use is contraindicated Patients with known hypersensitivity to Telmisartan, Hydrochlorothiazide, or any sulphonamide-derived substance. Patients with anuria, severe hepatic impairment, severe renal impairment (creatinine clearance < 30 mL/min), cholestasis/biliary obstructive disorders, or refractory electrolyte imbalances (e.g., hypercalcaemia).
Age-related eligibility rules Pediatric population (below 18 years) eligibility is not established (safety and efficacy data are insufficient). Geriatric patients are eligible, with no age-based dosage adjustment necessary.
Pregnancy and lactation eligibility status Contraindicated in the second and third trimesters of pregnancy. Use is not recommended during lactation or in the first trimester of pregnancy (discontinuation advised immediately upon detection of pregnancy).
Eligibility-related restrictions Contraindicated for use with aliskiren-containing products in patients with diabetes mellitus or renal impairment. Volume or salt depletion must be corrected prior to initiating therapy.

Connection to the overall eligibility profile:

Regulatory documents define who can and cannot use this medicine by establishing absolute contraindications tied to allergies, specific co-medication status, and non-compensable organ failure (severe hepatic/renal impairment). The pediatric population and pregnant/lactating patients are specifically categorized as having non-established or not recommended use, or as being absolutely contraindicated.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Polsart Plus defines several significant interaction patterns based on pharmacodynamic and pharmacokinetic outcomes. Co-administration with Aliskiren-containing products is formally contraindicated for patients diagnosed with Diabetes Mellitus or Renal Impairment (GFR less than 60 mL/min/1.73 m^2). This restriction is due to the potential for severe hypotension and hyperkalemia.

Documented Exposure and Efficacy Interactions

Use with Lithium may lead to a rise in its plasma concentration and toxicity because the renal clearance of Lithium is reduced. Co-administration with Non-steroidal anti-inflammatory drugs (NSAIDs) may result in a reduced blood pressure-lowering effect and increase the risk of renal impairment.

Substance and Timing Constraints

Other antihypertensive agents, such as ACE inhibitors, can intensify the risk of hypotension. Regarding administration timing, co-use with Cholestyramine or Colestipol should be separated by 4 hours to prevent reduced absorption of one component. The use of Potassium supplements and salt substitutes is restricted due to the increased risk of hyperkalemia. Additionally, Alcohol, barbiturates, or narcotics may potentiate orthostatic hypotension. Dosage adjustments for antidiabetic drugs may be required.

Mechanism of Action

Polsart Plus modulates systemic physiology through the coordinated action of two distinct compounds. The first component, Polsartan, functions as a highly selective competitive antagonist at the Angiotensin II type 1 ( AT1) receptor. By binding to the AT1 receptor, Polsartan prevents the vasoconstrictive and aldosterone-releasing effects mediated by Angiotensin II. This antagonism primarily occurs in vascular smooth muscle and the adrenal cortex, resulting in a reduction of peripheral vascular resistance.

The second component, a diuretic agent, acts directly in the kidney. It specifically inhibits the Na^+- Cl^- symporter (NCC) located on the luminal membrane of the distal convoluted tubule. Inhibition of the NCC reduces the reabsorption of sodium and chloride ions. This sustained natriuretic effect subsequently increases the osmotic excretion of water, which modulates extracellular fluid volume. The combined actions modify the AT1 signaling cascade and renal tubular ion transport to effect a modulation of systemic vascular tone and volume status.

Dosage and Administration Information

How to Use Polsart Plus

Polsart Plus is administered orally as a fixed-dose combination tablet and is taken once daily. The tablet should be swallowed whole with liquid and may be taken consistently either with or without food. Due to the product's sensitivity to moisture, the tablets are hygroscopic and must remain in the sealed blister pack until the moment of intake.


Use Pattern and Dose Titration

This combination product is not indicated for initial therapy for hypertension. Its application is reserved for adult patients whose blood pressure is not adequately controlled by Telmisartan monotherapy alone, establishing a second-line use pattern.

The available strengths are fixed combinations ranging from 40 mg/12.5 mg to 80 mg/25 mg (Telmisartan/Hydrochlorothiazide). The maximal blood pressure reduction is typically achieved after approximately four weeks of initiating a stable dose. If blood pressure remains uncontrolled after this period, the dosage can be titrated up to the highest permissible strength, with 80 mg/25 mg being a common maximum daily dose.


Administration in Specific Patient Groups

Specific dosage constraints apply for certain patient populations. For individuals with mild to moderate hepatic impairment, the daily dose must not exceed 40 mg/12.5 mg once daily. Furthermore, the combination is generally not recommended for use in cases of severe renal impairment (creatinine clearance le 30 mL/min) due to the presence of the diuretic component.

Recent Clinical Evidence

Polsart Plus: Recent Clinical Evidence

Evidence for Use in Essential Hypertension

The core research for the Telmisartan and Hydrochlorothiazide combination is based on randomized controlled trials (RCTs) in adults with essential hypertension, particularly those whose condition was not adequately addressed by Telmisartan taken alone. Studies reported measurements of greater blood pressure reductions in the combination groups compared to single-agent Telmisartan or a placebo. Findings also described that a higher percentage of patients receiving the combination were observed to have blood pressure measurements within the pre-specified target ranges used in the studies.

Evaluating Sustained Effect and Long-term Data

Researchers monitored the duration of the measured blood pressure changes using 24-hour Ambulatory Blood Pressure Monitoring (ABPM). Reported patterns described the consistency of the blood pressure changes over the full 24-hour period. While the main clinical trials that examined the combination's primary effect were generally short-term (12 weeks or less), researchers conducted longer-term extension studies to monitor the maintenance of blood pressure changes.

Research in Specific Patient Groups

Research has examined blood pressure changes in certain specific subgroups. These included older adults and individuals with co-existing conditions such as Type 2 diabetes and obesity. Studies monitored how outcomes related to systemic or functional imbalance evolved in these specific patient populations.

Research Gaps and Uncertainties

The primary research relies on surrogate endpoints (blood pressure). These findings do not directly measure the combination's association with long-term cardiovascular events such as heart attack or stroke. Limited data are available for long-term outcomes regarding the duration and consistency of blood pressure changes over multiple years, and more research is needed regarding the direct impact of the combination on these critical hard outcomes.

Key Studies & References

  1. Telmisartan/Hydrochlorothiazide: a review of its use as fixed-dose combinations in essential hypertension
  2. Telmisartan 80mg Plus Hydrochlorothiazide 25mg First Line in Moderate or Severe Hypertension (RCT Summary)
  3. Is the fixed-dose combination of telmisartan and hydrochlorothiazide a good approach to treat hypertension? (Review)

Frequently Asked Questions (FAQ)

Common questions about Polsart Plus (FAQ)


Q: How long does it typically take for Polsart Plus to start working effectively on blood pressure?

A: Studies indicate that while your blood pressure may begin to change sooner, the maximal blood pressure reduction from Polsart Plus is typically reached after approximately four weeks of initiating a stable dose. This is when the medication’s full, intended effects are generally observed.

Q: Is it normal to feel dizzy or lightheaded when first starting Polsart Plus?

A: Yes, regulatory documents state that dizziness and hypotension (low blood pressure) are common side effects of this medication. These effects are most likely to occur when you first begin treatment or if your dosage is increased. Patients may experience dizziness or lightheadedness when changing positions, such as rising quickly from a sitting or lying position.

Q: What are the most commonly reported side effects of Polsart Plus?

A: Official product information lists the most common side effects (affecting 1 to 10 users in 100) as dizziness, hypotension (low blood pressure), and fatigue. Other common events include symptoms related to infection, such as an upper respiratory tract infection.

Q: What should a patient do if they experience unusual fatigue or muscle weakness while on Polsart Plus?

A: Unusual weakness or fatigue, or muscle pains and cramps, can be signs of low potassium levels (hypokalemia), which can be caused by the diuretic component of the medicine. These symptoms are important to discuss with a healthcare provider.

Q: Can Polsart Plus affect blood sugar levels, and is this a common concern for non-diabetics?

A: The medication may increase blood sugar levels. Regulatory information notes that for patients who take antidiabetic drugs, a dosage adjustment may be required to manage this effect. This potential for metabolic changes is a documented caution in the official safety profile.

Q: Are there any specific over-the-counter (OTC) pain relievers or cold medicines to avoid while taking Polsart Plus?

A: Yes, Non-steroidal anti-inflammatory drugs (NSAIDs), which are common in OTC pain and cold medicines, may interact with Polsart Plus. Taking them together may reduce the blood pressure-lowering effect and increase the risk of kidney problems. The combination of these agents is noted in official documents as requiring caution.

Q: Is it necessary to avoid alcohol completely while taking Polsart Plus?

A: Official patient information advises that you should avoid or limit alcohol consumption. Alcohol may increase the risk of orthostatic hypotension (dizziness or fainting when standing up) due to its combined effect with the medication.

Q: Why is taking Polsart Plus with certain other heart medications, like digoxin, a concern?

A: Regulatory documents explicitly note a risk when combining Polsart Plus with the heart medication Digoxin. This is because the diuretic component can cause electrolyte changes that increase the risk of digitalis-induced heart rhythm disturbances.

Q: Does Polsart Plus contain lactose or other ingredients that might be concerning for allergies?

A: Some formulations of Polsart Plus may contain lactose as an inactive ingredient; official documents note that patients with sugar intolerances may need to discuss this ingredient with a healthcare provider. The medicine is also contraindicated for people allergic to any sulphonamide-derived substance.

Q: Can Polsart Plus be taken with or without food, and does it matter for its effectiveness?

A: Official prescribing information states that the tablet may be taken with or without food. Taking it consistently at the same time each day is key for its effectiveness, regardless of a meal.

Q: Can Polsart Plus cause electrolyte imbalance, and what are the signs of this?

A: Yes, the medication can cause electrolyte imbalances, such as low potassium (hypokalemia). Signs that may indicate an imbalance include seizures, dry mouth, muscle pains or cramps, or unusual tiredness or weakness. These symptoms are important to discuss with a healthcare provider.

Q: Why does Polsart Plus sometimes cause increased sensitivity to the sun?

A: The diuretic component of the medication, hydrochlorothiazide, is known to make the skin more sensitive to sunlight and ultraviolet (UV) radiation (photosensitivity). Official health warnings recommend protective measures for individuals taking this medication, such as limiting sun exposure and using protective clothing.

Q: Does Polsart Plus interact with common supplements like potassium or magnesium?

A: Official information advises that the use of Potassium supplements or salt substitutes containing potassium is restricted due to a risk of high potassium (hyperkalemia). Magnesium imbalance is also noted as a risk factor requiring monitoring for use with this medication.

Q: Are there any long-term effects of taking a diuretic like hydrochlorothiazide in a combination pill?

A: Regulatory authorities warn that prolonged use of hydrochlorothiazide may be associated with a cumulative, dose-dependent increased risk of non-melanoma skin cancer (e.g., basal cell carcinoma). Patients on long-term therapy may benefit from regular skin checks, as noted in official safety warnings.

Q: Can Polsart Plus cause an increase in uric acid, leading to concerns about gout?

A: Official warnings state that the medication may increase the concentration of uric acid in the blood (hyperuricemia). Regulatory information advises caution because this may trigger or worsen gout in individuals who are susceptible.

Q: How does the diuretic component of Polsart Plus (hydrochlorothiazide) affect urination frequency?

A: Hydrochlorothiazide is classified as a diuretic (or water pill). Its mechanism of action involves making the kidneys remove unneeded water and salt from the body, which naturally leads to an increase in urination frequency.

Q: Is it common for people to switch from a different ARB to Polsart Plus, and why might that happen?

A: The medication is typically used when a patient’s blood pressure is not adequately controlled by the active ingredient Telmisartan taken alone. Therefore, patients may be switched to this combination when they need the added blood pressure-lowering effect provided by the diuretic component.

Q: Is there a risk of developing a skin rash or hives when taking Polsart Plus?

A: Official safety information lists rash and hives (urticaria) as potential side effects. Patients should be aware that swelling of the face, lips, or throat (angioedema) is a rare but serious form of allergic reaction.

Q: Does Polsart Plus have any known effect on sexual drive or performance?

A: Official regulatory listings include reports of a decreased interest in sexual intercourse, inability to have or keep an erection (impotence), or a change in sex drive or performance as potential side effects.

Q: Can Polsart Plus increase the risk of developing a new skin cancer (non-melanoma skin cancer)?

A: Yes, official safety warnings from health authorities state that the long-term use of the diuretic component, hydrochlorothiazide, has been associated with an increased risk of non-melanoma skin cancer. Official safety warnings recommend that individuals taking this medicine limit sun exposure and that skin checks be considered regularly.

Q: How are the risks of Polsart Plus assessed for older patients (e.g., over 60 years of age)?

A: Regulatory documents note that while older patients are eligible, they may be more likely to have age-related problems with the liver, kidneys, or heart. These conditions might require caution or potential dosage adjustments, but no automatic age-specific dosage change is required for the geriatric population.

Q: Can Polsart Plus affect one's ability to drive or operate machinery?

A: Yes, because the medication can occasionally cause side effects like dizziness, syncope (fainting), or vertigo. Official patient warnings note that performing hazardous tasks, such as driving or operating heavy machinery, should be done with caution until a patient is aware of the medicine's effects.

Q: Can Polsart Plus be safely used by people with a history of gallbladder issues or gallstones?

A: Official warnings state that Polsart Plus should be used with caution in patients with a history of gallbladder disease or gallstones. This is because the medication has the potential to make these existing conditions worse.

Q: What kind of evidence is available on Polsart Plus and its use for cardiovascular risk reduction?

A: The core research for the Telmisartan/Hydrochlorothiazide combination is based on surrogate endpoints, specifically blood pressure reduction. Regulatory agencies note that controlled trials demonstrating a reduction in long-term cardiovascular events, such as heart attack or stroke, are not available for the combination product.

Q: Can Polsart Plus affect cholesterol or lipid levels in the blood?

A: Yes, regulatory documents note that the medication may cause or worsen hypercholesterolemia (high cholesterol) or other lipid-related imbalances. High cholesterol is listed as a condition that may be made worse by the diuretic component.

Q: Why must patients with a history of sulfa drug allergies be cautious about Polsart Plus?

A: Polsart Plus is contraindicated for patients allergic to the active ingredient hydrochlorothiazide, or to any sulfonamide-derived substance (sulfa drugs). This is because the diuretic component, hydrochlorothiazide, is chemically derived from the sulfonamide class.

How should Polsart Plus be stored and disposed of?

How to Store and Dispose of Polsart Plus?

The official storage and disposal guidelines for Polsart Plus (Telmisartan/Hydrochlorothiazide) are defined by the product's stability needs and regulatory mandates.


Storage Requirements

The tablets do not require any special temperature storage conditions. However, due to the hygroscopic nature of the medication, it is mandatory to store the product in its original package and keep it in the sealed blister until immediately before administration to ensure protection from moisture. Like all medicines, Polsart Plus must be kept out of the sight and reach of children.


Disposal Instructions

Unused or expired Polsart Plus must be handled according to strict environmental guidelines. The medication should not be disposed of via wastewater or household waste. It must be discarded in accordance with local requirements for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Polsart Plus found in:

A-Z Index: